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INTRODUCTION
Since its discovery in 1982, 
interest in the role of Helicobacter 
pylori in determining human 
pathologies has grown and it 
has been recognised as one of 
the key factors responsible for 
many gastric and extra-gastric 
pathologies. Recently  it has been 
also suggested as a causal agent 
of drug malabsorption. There 
is evidence that this infection 
REVIEW
ABSTRACT
Background & Aims: Helicobacter pylori (H. pylori) infection has been suggested as a cause of impaired drug 
absorption. his infection leads to alteration of the gastric acid secretion that may change the conformational 
characteristics of drugs and their intestinal absorption leading to uncertainties about the dose to administer 
and the therapeutic results. A systematic review was undertaken to clarify the implications of  drug absorption 
during the administration of replacement therapies.
Methods: Electronic databases such as MEDLINE/Pubmed, EMBASE and he Cochrane Library [which 
includes Cochrane Database of Systematic Review (CDSR), the Cochrane Central Register of Controlled Trials 
(CENTRAL), the Database of Abstract of Reviews of Efect (DARE)] were searched. Grey literature databases 
(e.g. the International clinical trials registry platform, Trials Register, Clinical Trials.gov, Controlled Trials 
and TrialsCentral), heses database, Government publication and LILACS database were also searched. No 
language restriction was applied.
Results: Infection and altered drug absorption were evaluated in patients under replacement therapies with 
iron, thyroxin and L-dopa. In all, seven studies included an improvement in drug absorption ater eradication 
and an existing inverse correlation between the grade of gastric inlammation and indices of drug absorption 
were noticed. 
Conclusion: his systematic review conirmed the presence of an interaction between  infection and drug 
absorption of orally administered replacement therapies. Gastric acid reduction and subsequent alteration of 
drug composition seem to lead this mechanism. Clinicians should be aware of this possible interaction when 
starting a replacement therapy in patients and when evaluating poor clinical response.
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is one of the principal determinants of altered gastric acid 
secretion whose severity depends on the extension of the 
infection in the stomach and on the duration of the disease 
[1]. Despite the fact that this infection can potentially alter 
the bioavailability of any drug, those who are part of a therapy 
designed to compensate for a lack or deiciency arising from 
inadequate nutrition, dysfunctions or losses (replacement 
therapies) are more likely to be afected by its presence and are 
potentially of high clinical interest due to the close relationship 
between the drug efect and the dose administered. herefore, 
the objective of this systematic review is to assess the efect of 
eradication on drugs absorption in patients undergoing oral 
replacement therapy.
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METHODS
Search methods for study identiication
Key electronic databases such as the Cochrane Library 
[which includes the Cochrane Database of Systematic Review 
(CDSR), the Cochrane Central Register of Controlled Trials 
(CENTRAL) and the Database of Abstracts of Reviews of Efect 
(DARE)], MEDLINE/Pubmed, EMBASE and LILACS database 
(Latin American and Caribbean Health Sciences Literature) 
were screened. To identify additional records these sources 
were included: International clinical trials registry platform 
(http://www.who.int/trialsearch); ClinicalTrials.gov (http://
www.clinicaltrials.gov), Current Controlled Trials (http://
www.controlled-trials.com/) and TrialsCentral (http://www.
trialscentral.org), theses database (http://www.theses.com/) 
and Government publications (http://www.opengrey.eu/). he 
PICO strategy (Population, Intervention, Comparator and 
Outcomes) was used to select appropriate terms for the search: 
helicobacter pylori/H.P./positive/infection were combined with 
“replacement therapy”, “nutrients”, “micronutrients”, “nutrient 
replacement”, “vitamins”, “trace elements” and “absorption” 
with appropriate Boolean operator (Supplementary material: 
Appendix 1, available from http://www.jgld.ro/2015/1/16.
html). Abstracts and conference proceedings from the United 
European Gastroenterology Week (published in Gut), Digestive 
Disease Week (published in Gastroenterology), and European 
Helicobacter Pylori Study Group (published in Helicobacter) 
from January 2012 to January 2014 were also hand-searched. 
Experts in the ield were also contacted to supply information 
about unpublished or ongoing researches and to double check the 
electronic searches for missing studies identiication.
Study inclusion and exclusion criteria
he participants considered were people over 16 years with 
H. pylori infection that had underwent replacement therapy 
independently from the histological grading of their infection-
related gastric inlammation. hey were considered positive for 
H. pylori infection if at least one test of the following: histology, 
rapid urease test (RUT), culture, serology, urea breath test 
(13C-UBT) and stool antigen test (SAT) was positive. If studies 
were a mixture of participants with impaired acid production 
due to H. pylori infection and other medical conditions (e.g. 
autoimmune atrophic gastritis or chronic proton pump 
inhibitor-PPI therapy), data regarding participants with 
the infection were extracted and analyzed separately. Oral 
replacement therapy was referred to any treatment orally 
administered to “compensate for a lack or deiciency arising from 
inadequate nutrition, from certain dysfunctions (glandular hypo-
secretion), or from losses (hemorrhage)” [2] whose efectiveness 
was evaluated in a routine clinical practice to inform a clinical 
decision (e.g. dosage to administer).
H. pylori eradication treatment was considered efective if 
administered for at least one week with an achieved eradication 
rate of at least 70%. Eradication status was considered valid if 
assessed from 4 to 6 weeks ater the end of the treatment by 
13C-UBT or SAT. Eleven randomized trials and observational 
studies (cohort studies, case-control and case-series) were 
included in the search to explore the impact of the intervention 
on the primary outcome in routine clinical practice. Meta-
analyses and reviews were not included but their references 
were scanned to ind additional primary studies. 
No language restrictions were used. 
Selection procedure
Relevant studies were analyzed and extracted by two 
unblinded reviewers (G.F. and V.C.) using a form adapted from 
he Cochrane Data Extraction and Assessment Form [3]. Data 
collected included title, irst author, year of publication, type 
of publication (full text/ abstract, published/ unpublished), 
language, study design, characteristics of the population, 
disease/condition that needs replacement therapy, type of 
replacement therapy, type of H. pylori infection assessment, 
histological grading of gastric inlammation, if present, and 
assessment of hypochlorhydria, type of eradication treatment 
administered, type of outcome measurement performed, 
presence of adverse efects due to eradication therapy and drug 
absorption modiication. he quality of studies as Randomised 
Controlled Trials (RCTs), randomised cluster trials and 
randomised cross-over trials, non-randomised controlled 
trials (NRCTs) and controlled before-ater (CBA) studies 
was assessed by an adapted form of the Risk of Bias Criteria 
for EPOC reviews proposed by the Cochrane Public Health 
Group [4]. he quality of observational studies was assessed 
using an adaptation of the chart proposed by Petticrew et al. 
(2006) [5]. Diferences and disagreements were discussed and 
resolved by consensus. 
RESULTS 
he database searches were conducted in April 2014 
and identified 3,400 potentially relevant findings. No 
further relevant records were identiied through the hand-
search of abstracts and conferences.  Ater duplicates had 
been removed, 3,109 out of 3,400 records were evaluated 
independently by two unblinded reviewers. A summary of 
the process is showed in a low diagram according to the 
PRISMA Statement [6] (Fig. 1).
A total of seven studies were selected for review of the 
full paper and data extraction [7-13]. The high clinical 
heterogeneity detected in primary studies due to diferent types 
of intervention administered, diferent outcomes described 
and the low number of identiied studies did not allow us 
to pool data together to produce a summary measure and 
to perform statistical evaluation. However, the systematic 
approach that was used made it possible to evaluate the efect 
of the intervention between studies on the same replacement 
therapy and to speculate about the presence of a common 
pattern among studies on diferent drugs [14]. Characteristics 
of the included studies are shown in Table I.
H. pylori eradication and thyroxine
Two studies explored the efect of H. pylori eradication 
therapy on thyroxine absorption by looking at thyroid 
function test commonly used to check the efect of thyroxine 
replacement therapy. hey both performed thyroid function 
tests before and after the administration of eradication 
treatment and noticed a statistically signiicant improvement in 
the results. In particular, in the study by Centanni et al. [7], the 
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daily need for thyroxine was nearly reversed ater eradication 
treatment and was associated with a decrease in thyrotropin 
levels that was calculated to be near 94% [15]. Similar results 
were obtained by Bugdaci et al. (2011) [12], who noticed a 
statistically signiicant improvement in thyroid function tests 
ater H. pylori eradication in all of the enrolled cases. hey also 
noticed the development of a clinical condition related to an 
excessive absorption of thyroxine (thyrotoxicosis) in 21% of 
cases ater the cure of the infection. 
H. pylori eradication and L-Dopa absorption
Two studies evaluated the efect of H. pylori eradication 
treatment on L-dopa absorption [9, 10]. he efect of the 
treatment was evaluated on the pharmacokinetic and clinical 
response to L-dopa in patients with advanced Parkinson’s 
disease and H. pylori infection. 
he irst study was a case series of six patients where the 
authors demonstrated that the eradication treatment led 
to a 21% increase in L-dopa plasma concentration and a 
concomitant clinical beneit. hey subsequently conirmed 
their results in a RCT where patients were randomly divided 
in two groups and received either eradication therapy 
or placebo. In this study, the eradication therapy group 
achieved a 54% increase in L-dopa absorption and showed 
signiicant symptom improvement. his positive relationship 
was reinforced by the absence of L-dopa pharmacokinetics 
and symptoms improvement in two patients that failed the 
eradication.  
H. pylori eradication and iron absorption
All studies that explored the efect of H. pylori eradication 
on iron absorption concluded that H. pylori infection is 
associated with a poorer response to oral iron therapy, that its 
treatment can enhance the eicacy of oral iron replacement 
therapy and that the screening for this infection should be 
considered in patients with unexplained or refractory iron 
deiciency anemia [4, 8, 16]. Results of the case series performed 
by Kotb et al. (2012) [13] showed a statistically signiicant 
increase in haematological indices such as haemoglobin (Hb), 
serum ferritin (SF) and transferrin saturation (TF) achieved 
ater H. pylori eradication compared to baseline at 6 and 12 
weeks post therapy. hey also noticed a signiicant inverse 
correlation with the above mentioned parameters and the 
grade of inlammation detected in the stomach. heir results 
were supported by the indings of two randomised trials [8, 
11] that explored also changes in iron related parameters in 
blood ater H. pylori eradication. All three studies considered 
a slightly diferent panel of iron related parameters other than 
haemoglobin, which was a shared surrogate outcome for the 
evaluation of the efectiveness of iron replacement therapy. 
Hemoglobin values signiicantly increased ater eradication 
in all the studies.
Quality assessment of included studies
he quality of included studies was assessed independently 
by two unblinded reviewers (G.F. and V.C.) and diferences were 
discussed and solved by consensus. Each study was labelled at 
Fig. 1. PRISMA low diagram
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a “Low, “Medium” or “High” risk of bias taking into account 
the study design and the potential impact of the identiied 
bias. An adapted form of the Risk of Bias Criteria for EPOC 
reviews proposed by the Cochrane Public Health Group (CPHG, 
2011) was used for RCTs and NRCTs, while the quality of 
Observational Studies was assessed using an adaptation of the 
chart proposed by Petticrew et al. [5]. 
Based on the results of the assessment performed, case 
series on the relationship between H. pylori eradication and 
thyroxine absorption [7, 12] were considered of medium 
quality. he two studies performed by Pierantozzi et al. [9, 10] 
on L-dopa absorption ater H. pylori treated infection were 
a case series and a randomised trial and were considered of 
low and high quality, respectively. Finally, studies on H. pylori 
eradication and iron absorption were evaluated as being of low 
quality [8, 11] and medium quality [13], respectively. 
DISCUSSION
his systematic review provides strength to the hypothesis 
that there is an inverse relationship between H. pylori 
infection and drug absorption. Although this link has been 
previously evaluated [13], this review focused on a particular 
category of drugs which are frequently used in routine clinical 
practice and whose dosage and clinical efectiveness strictly 
depends on the amount of drug absorbed; with appropriate 
restrictions and speciications they have been referred to as 
“replacement therapies” because they are used to compensate 
for a lack or deiciency arising from inadequate nutrition, 
dysfunctions or losses. It has been noticed that, independently 
from the drug considered, there is a positive modiication in 
replacement therapies absorption ater H. pylori eradication 
[17]. his modiication can be seen both directly by using 
pharmacokinetics indices (AUC and Cmax) and/or indirectly 
through the modiication of speciic parameters in blood tests 
or through clinical scores. 
hose indings suggested a possible mechanism that relates 
the infection and drug absorption based on alterations in 
gastric acidity. Previous studies have reported that the intestinal 
absorption of thyroxine, L-Dopa and iron are pH-dependent 
[7, 18, 19]. However, only two studies on thyroxine absorption 
[7, 12] and one study on iron absorption [13] explored the 
correlation between the grade of H. pylori related gastritis 
in gastric biopsies, its location in the stomach mucosa (e.g. 
Table I. Characteristics of included studies
Drug Study design Participants H. pylori diagnosis Intervention/s Outcome
Bugdaci 
(2011) [12]
hyroxine Case series 32 patients with 
hypothyroidism 
Age: 39.6 ±11 y (SD) 
M/F: 84% female
Histology Eradication with standard 
triple therapy  (Is tine) or 
quadruple therapy (IInd 
line) for 14 days
Modiications in 
thyroid function 
tests (TSH, fT3, 
FT4)
Centanni 
(2012) [7]
hyroxine Case series 
subgroup of a case-
control study
269 patients with 
hypothyroidism: 113 
with hypochloridria, 
135 with no gastric 
disorders. 11 patients 
with  infection 
eradicated  
Age: 44 y (median)
M/F: 100% female
Histology and/or 
serology for 269 
but reassessed with 
13C-UBT for the 
11 pts in the case 
series
Eradication with standard 
triple therapy for 14 days
Modiications in 
thyroid function 
test (TSH)
Pierantozzi 
(2001) [9]
L-Dopa Case series 6 patients with 
advanced PD 
Age: 57.0±9.7y (mean) 
M/F: not speciied.
Serology H. pylori eradication with 
standard triple therapy for 7 
days vs placebo
L-dopa AUC 
and clinical 
improvement 
(UPDRS score)
Pierantozzi 
(2006) [10]
L-Dopa RCT double blind, 
parallel group 
design
34 patients with PD 
Age: 65.55 ±7.6y 
(mean) 
M/F:53% female
Serology, stool test, 
histology and RUT
H. pylori eradication with 
standard triple therapy 
for 7 days vs antioxidant 
(allopurinol)
L-dopa AUC, 
Cmax and clinical 
improvement 
(UPDRS score)
Valiyaveettil 
(2005) [11]
Iron RCT 52 patients 
Age: 30-49 y (range) 
M/F: 75% female
Histology, RUT H. pylori eradication with 
standard triple therapy for 
7 days + ferrous sulphate vs 
oral ferrous sulphate alone + 
delayed H pylori eradication 
(during second month) vs 
ferrous sulphate alone
Improvement in 
iron indices (Hb, SI 
and SF)
Chen (2007)
[8]
Iron RCT 86 patients Age: 18-76 
y (range) M/F:42% 
female
13C-UBT H. pylori eradication with 
standard triple therapy for 
14 days + ferrous succinate 
vs oral ferrous succinate 
alone
Improvement in 
iron indices (Hb, 
SI, SF, MCH and 
MCV)
Kotb (2012)
[13]
Iron Case series 20 patients Age: 25-55 
y (range) M/F: 60% 
female
Histology H. pylori eradication with 
sequential therapy +iron 
sulphate
Improvement in 
iron indices (Hb, 
SF and transferrin)
PD: Parkinson᾿s disease; SI: sideremia; SF: serum ferritin; MCH: mean Hb concentration; MCV: mean corpuscular volume; Hb: hemoglobin; RUT: rapid 
urea test; 13C-UBT: urea breath test
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antrum or corpus), the gastric pH and drug absorption with 
pre and post eradication changes.  Hypochloridria is not the 
only possible explanation of impaired drug absorption in H. 
pylori positive patients. Past studies on L-dopa showed that 
H. pylori infection can cause a delayed gastric emptying. his 
may be responsible for modiications in the normal pathway of 
drug absorption by favouring a bacterial overgrowth that can 
compete with absorption mechanisms and by increasing the 
contact time between a substance and gastric enzymes [20]. 
Alternatively, for iron it has been speculated that H. pylori can 
actively compete with the body for its absorption [21]. Iron 
also needs to be transformed into an absorbable form and this 
is achieved both by the presence of an appropriate gastric pH 
and by the presence of ascorbic acid secreted in gastric juice. 
H pylori infection alters both mechanisms [22]. 
Chronic blood loss related to H. pylori gastritis can be 
another reasonable cause of iron depletion and poor response 
to orally administered replacement therapy. However, not all 
patients with H. pylori gastritis develop iron deiciency anemia, 
suggesting that more than one mechanism can be involved [23]. 
From these indings it is clear that drugs absorption is a 
complex mechanism that still needs to be fully understood. 
his review provided strength to the hypothesis that H. pylori 
infection plays an important role in drug metabolism and 
that it is one of the leading cause in altering the mechanisms 
of drug absorption. 
he implications of impaired drug absorption in subjects 
with H. pylori infection can be relevant for clinical practice 
due to the high prevalence of the infection worldwide [24]. 
At the same time, clinical conditions that need replacement 
therapies, such as hypothyroidism, iron deiciency anemia and 
Parkinson’s disease, are widespread. It has been estimated that 
about 4.6% of the United States population has hypothyroidism, 
increasing with age to more than 10% in adults above 65 years 
old [15, 16]. Iron deiciency anemia is even more prevalent, 
with 30% of the world population afected [26]. Finally, an 
estimated seven to ten million people worldwide are living 
with Parkinson‘s disease [27]. 
he presence of a relationship between drug absorption and 
H. pylori raises further questions regarding the opportunity 
to change our clinical practice. Ideally, patients that need to 
start a replacement therapy as well as patients currently under 
therapy should be screened for H. pylori infection. Moreover, 
the dosage of the administered drugs should be re-evaluated, 
with a diferent timing in patients that have been eradicated 
to avoid overdose and related side efects.
What diferentiates this infection from other causes of 
impaired drug absorption is that alterations related to the 
presence of H. pylori are reversible once the bacteria is eradicated 
with an antibacterial therapy [28]. However, the administration 
of an eradication treatment for every person diagnosed with 
H. pylori infection will cost more than $32 billion in the Unites 
States alone [29]. his underlines that a clear strategy is required 
to target appropriately people that would beneit from the 
eradication treatment. his review can contribute to this aim 
by highlighting speciic clinical conditions that improve ater 
H. pylori eradication and by targeting subgroups of patients 
that need to be screened for H. pylori positivity before being 
administered replacement therapies. 
Despite the fact that results on the relationship between 
H. pylori and drug absorption that have been obtained in this 
review are consistent, there are several limitations that need to 
be highlighted: the paucity of studies available for inclusion, 
the limitations of the available data and the methodological 
weaknesses that have been evaluated. hese determine the 
need to consider these results as non-deinitive. Moreover, the 
statistical signiicance of the results could not fully correspond 
to a clinical signiicance that needs to be further explored with 
better quality studies.
CONCLUSIONS 
This systematic review has found a small number of 
studies that support the hypothesis of an existing interaction 
between H. pylori infection and drug absorption of orally 
administered replacement therapies. Clinicians should be 
aware of this possible interaction when initiating a replacement 
therapy in a new patient and when evaluating poor clinical or 
laboratory response in patients under chronic treatments. he 
optimization of the medical therapy to obtain the best result 
with the lowest number of side efects should be the goal of 
any correct therapeutic approach. However, the limitations that 
have been highlighted and the scarcity of good quality studies 
on this topic underline the necessity of a greater number of 
studies on this subject and of better quality.
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Appendix 1: Literature search strategy 
Database: OvidMEDLINE ( http://ovidsp.ovid.com ) 
Searched from 1946 to February Week 4 2014 
The following search strategy was used in MEDLINE and then adapted  
as necessary for other databases: 
1 helicobacter pylori.mp. or exp Helicobacter pylori/ (32600) 
2 exp Helicobacter Infections/ or h pylori.mp. (29173) 
3 helicobacter infection*.tw. (430) 
4 (helicobacter adj3 positive).tw. (1017) 
5 (h pylori adj3 infect*).tw. (10344) 
6 1 or 2 or 3 or 4 or 5 (34132) 
7 exp Thyroxine/ or exp Estrogen Replacement Therapy/ or exp Hypothyroidism/ or   
        replacement therapy.mp. (105969) 
8 replacement therap*.tw. (34229) 
9 drug* replacement therap*.tw. (6) 
10 nutrient* replacement*.mp. (14) 
11 nutrient* deficien*.tw. (948) 
12 micronutrients/ or trace elements/ or vitamins/ (32151) 
13 7 or 8 or 9 or 10 or 11 or 12 (139951) 
14 exp Absorption/ or exp Intestinal Absorption/ or absorption*.mp. (193293) 
15 drug* absorption*.tw. (2787) 
16 absorb*.mp. (83454) 
17 (impaired adj3 absorption*).tw. (767) 
18 (reduced adj3 absorption*).tw. (1960) 
19 (altered adj3 absorption*).tw. (337) 
20 malabsorption*.mp. (13722) 
21 14 or 15 or 16 or 17 or 18 or 19 or 20 (265372) 
22 6 and 13 (80) 
23 6 and 21 (427) 
24  22 or 23 (489) 
 
